• Port-a-Patch

    世界上最小的膜片钳系统
  • Port-a-Patch

    易学易用——教学的理想工具
  • Port-a-Patch

    可记录细胞、细胞器与脂双层
  • Port-a-Patch

    世界上首款平板芯片膜片钳设备
  • Port-a-Patch

    可进行内灌流——更换细胞内液的理想工具

2014 - A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV

icon pap  Port-a-Patch publication in Nature Communications (2014)

Authors:
Chen C.C., Keller M., Hess M., Schiffmann R., Urban N., Wolfgardt A., Schaefer M., Bracher F., Biel M., Wahl-Schott C., Grimm C.

 

Journal:
Nat Commun (2014) 5(4681):1-10


Abstract:
Mucolipidosis type IV (MLIV) is an autosomal recessive lysosomal storage disorder often characterized by severe neurodevelopmental abnormalities and neuro-retinal degeneration. Mutations in the TRPML1 gene are causative for MLIV. We used lead optimization strategies to identify—and MLIV patient fibroblasts to test—small-molecule activators for their potential to restore TRPML1 mutant channel function. Using the whole-lysosome planar patch-clamp technique, we found that activation of MLIV mutant isoforms by the endogenous ligand PI(3,5)P2 is strongly reduced, while activity can be increased using synthetic ligands. We also found that the F465L mutation renders TRPML1 pH insensitive, while F408Δ impacts synthetic ligand binding. Trafficking defects and accumulation of zinc in lysosomes of MLIV mutant fibroblasts can be rescued by the small molecule treatment. Collectively, our data demonstrate that small molecules can be used to restore channel function and rescue disease associated abnormalities in patient cells expressing specific MLIV point mutations.


Download here

返回总览

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.